Certolizumab pegol
TNF alpha | |
Clinical data | |
---|---|
Trade names | Cimzia |
Other names | CDP870 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608041 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | about 11 days |
Excretion | Kidney (PEG only) |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C2115H3252N556O673S16 |
Molar mass | 47749.46 g·mol−1 |
(what is this?) (verify) |
Certolizumab pegol, sold under the brand name Cimzia, is a
It is on the World Health Organization's List of Essential Medicines.[7]
Medical uses
- Crohn's Disease
- On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.[5][8][9]
- Rheumatoid arthritis
- On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA on October 1, 2009.[10]
- Psoriatic arthritis
- On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis.[11]
Method of action
Certolizumab pegol is a monoclonal antibody directed against
Clinical trials
- Crohn's disease
- Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.[2][13][14][15]
- Axial spondyloarthritis
- In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis.[16]
- Rheumatoid arthritis
- Certolizumab appears beneficial in those with rheumatoid arthritis.[17]
References
- FDA. Retrieved October 22, 2023.
- ^ PMID 17634458.
- PMID 20190560.
- S2CID 21974683.
- ^ a b "Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160". U.S. Food and Drug Administration (FDA). December 24, 1999. Retrieved July 18, 2020.
- ^ "Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution". DailyMed. April 24, 2020. Retrieved July 18, 2020.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease". UCB press release. Archived from the original on February 18, 2012. Retrieved April 22, 2008.
- ^ Waknine Y (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. Retrieved May 1, 2008.
- ^ "Cimzia European Public Assessment Report". European Medicines Agency. Archived from the original on November 9, 2009. Retrieved November 15, 2009.
- ^ "Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis". Archived from the original on October 1, 2013. Retrieved October 1, 2013.
- PMID 28124979.
- ^ a b Schreiber S, Khaliq-Kareemi M, Lawrance I, Hanauer S, McColm J, Bloomfield R, Sandborn W (2005). "Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise)". Gut. 54 (suppl 7): A82.
- ^ Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, McColm JA, Innes A, Schreiber S (2006). "Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1)". Gastroenterology. 130 (4): A107.
- ^ "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease" (Press release). UCB. October 23, 2006. Archived from the original on March 29, 2020. Retrieved November 15, 2009.
- .
- PMID 28884785.
External links
- certolizumab+pegol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)